» Articles » PMID: 33462208

Hsa_circ_0007456 Regulates the Natural Killer Cell-mediated Cytotoxicity Toward Hepatocellular Carcinoma Via the MiR-6852-3p/ICAM-1 Axis

Overview
Journal Cell Death Dis
Date 2021 Jan 19
PMID 33462208
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Circular RNAs (circRNAs) is one type of important non-coding RNAs that participate in tumorigenesis and cancer progression. In our previous study, we performed a microarray analysis of circRNAs between the tumor tissues and the adjacent normal tissues of hepatocellular carcinoma (HCC) patients, and found that the circRNA hsa_circ_0007456 is significantly downregulated in the tumor tissues and correlated with the prognosis of HCC. We further investigated the relationship between the expression levels of hsa_circ_0007456 in HCC and the susceptibility of NK cells, and found that the expression levels of hsa_circ_0007456 in HCC cell lines significantly influenced their susceptibility to NK cells. Through a series of screening and validation, we found that hsa_circ_0007456 mainly functioned through sponging miR-6852-3p and regulating the expression of intercellular adhesion molecule-1 (ICAM-1) in HCC. The miR-6852-3p/ICAM-1 axis is essential for the NK cytotoxicity toward HCC mediated by hsa_circ_0007456. In conclusion, we identify here hsa_circ_0007456 as a promising biomarker of HCC, and highlight hsa_circ_0007456/miR-6852-3p/ICAM-1 axis as an important signaling pathway in the process of tumor immune evasion and the tumorigenesis of HCC.

Citing Articles

Circular RNAs: key players in tumor immune evasion.

Sanati M, Ghafouri-Fard S Mol Cell Biochem. 2025; .

PMID: 39754640 DOI: 10.1007/s11010-024-05186-8.


Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.

Hashemi M, Khosroshahi E, Daneii P, Hassanpoor A, Eslami M, Koohpar Z Noncoding RNA Res. 2024; 10:98-115.

PMID: 39351450 PMC: 11440256. DOI: 10.1016/j.ncrna.2024.09.006.


Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.

Racca L, Liuzzi E, Comparato S, Giordano G, Pignochino Y Int J Mol Sci. 2024; 25(16).

PMID: 39201617 PMC: 11354327. DOI: 10.3390/ijms25168934.


Circular RNAs in tumor immunity and immunotherapy.

Zhang W, Xu C, Yang Z, Zhou J, Peng W, Zhang X Mol Cancer. 2024; 23(1):171.

PMID: 39169354 PMC: 11337656. DOI: 10.1186/s12943-024-02082-z.


Recent research progress of circular RNAs in hepatocellular carcinoma.

Li Z, Li Y, Lu J, Liang S, Zhang C, Zeng L Front Oncol. 2024; 13:1192386.

PMID: 38322286 PMC: 10844539. DOI: 10.3389/fonc.2023.1192386.


References
1.
Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J . The emerging landscape of circular RNA in life processes. RNA Biol. 2016; 14(8):992-999. PMC: 5680710. DOI: 10.1080/15476286.2016.1220473. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Shimasaki N, Jain A, Campana D . NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3):200-218. DOI: 10.1038/s41573-019-0052-1. View

4.
Kristensen L, Hansen T, Veno M, Kjems J . Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2017; 37(5):555-565. PMC: 5799710. DOI: 10.1038/onc.2017.361. View

5.
Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z . Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019; 18(1):130. PMC: 6714090. DOI: 10.1186/s12943-019-1047-6. View